{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:06:27Z","timestamp":1767650787083,"version":"3.28.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple Sclerosis (MS) a central nervous system autoimmune disorder, mainly affecting young adults and more prevalent among women, can lead to sexual dysfunction (SD) among both males and females with MS. Female sexual dysfunction can be defined as dyspareunia, a lack of sexual desire, disorders in the arousal and orgasm phases, and sexual pain disorders. The purpose of this study is to investigate the changes in sexual function among females with MS whose treatment was switched from first-line injectable medications to other agents after a six-month duration. And assess the changes in all three domains of SD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this longitudinal study females diagnosed with MS, aged between 18 and 50 years old, and were candidates for switching their treatment from interferon beta-1a (intra-muscular and subcutaneous), and Glatiramer Acetate (GA), to Fingolimod, Dimethyl Fumarate (DMF), or Natalizumab (NTZ) due to patients\u2019 convenience and tolerability and adverse events were included. \u201cMultiple Sclerosis Intimacy and Sexuality Questionnaire-19\u201d was used to evaluate the SD changes before and six months after the new treatment initiation. Statistical analysis was conducted using SPSS V.24 software. Histograms and the Shapiro-Wilk test were used to assess the normality of the variables; due to the non-normal distribution of quantitative variables (except for age), the Wilcoxon signed-rank test was used to compare the scores, before and six months after the medication change. The level of significance was considered less than 0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 107 female participants (average age: 35.09\u2009\u00b1\u20095.61), The mean of overall MSISQ-19 scores, before and six months after the medication change were not significant (p-value\u2009=\u20090.091). However, considering the subdomains, the medication changes only affected the tertiary subdomain of MSISQ-19 (p-value\u2009=\u20090.017). Still, the scores of other subdomains did not change significantly (p-value\u2009=\u20090.761 for primary SD and 0.479 for secondary SD). Also, there wasn\u2019t any significant difference between EDSS before and after the medication change (p-value\u2009=\u20090.461).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>To our knowledge, this was the first study, assessing the effect of MS medication change on the improvement of SD among patients. According to the results of the presented cross-sectional study, we found that during a six-month period, the tertiary subdomain of MSISQ-19 symptoms improved significantly, while the changes in other SD domains were not significant.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-024-03765-2","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T08:11:33Z","timestamp":1721808693000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Switching from injectable to other Disease Modifying Therapies may improve sexual dysfunction in people with Multiple Sclerosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Sara","family":"Ala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amirkafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosar","family":"Kohandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sareh","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Ghajarzadeh M et al. Prevalence of multiple sclerosis (MS) in Zanjan province of Iran. Int J Prev Med, 2020. 11.","key":"3765_CR1","DOI":"10.4103\/ijpvm.IJPVM_419_19"},{"issue":"5","key":"3765_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1352458519892491","volume":"26","author":"RR Voskuhl","year":"2020","unstructured":"Voskuhl RR. The effect of sex on multiple sclerosis risk and disease progression. Multiple Scler J. 2020;26(5):554\u201360.","journal-title":"Multiple Scler J"},{"issue":"14","key":"3765_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Multiple Scler J. 2020;26(14):1816\u201321.","journal-title":"Multiple Scler J"},{"key":"3765_CR4","doi-asserted-by":"publisher","first-page":"102525","DOI":"10.1016\/j.msard.2020.102525","volume":"46","author":"AL Christopoulos","year":"2020","unstructured":"Christopoulos AL, Poulios A, Pavlopoulos V. The relationship between dimensions of mental health and alexithymia in multiple sclerosis patients. Multiple Scler Relat Disorders. 2020;46:102525.","journal-title":"Multiple Scler Relat Disorders"},{"issue":"5","key":"3765_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/1352458513503598","volume":"20","author":"LC Schairer","year":"2014","unstructured":"Schairer LC, et al. The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis. Multiple Scler J. 2014;20(5):610\u20136.","journal-title":"Multiple Scler J"},{"issue":"6","key":"3765_CR6","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1002\/hep.30359","volume":"69","author":"SF Neong","year":"2019","unstructured":"Neong SF, Billington EO, Congly SE. Sexual dysfunction and sex hormone abnormalities in patients with cirrhosis: review of pathogenesis and management. Hepatology. 2019;69(6):2683\u201395.","journal-title":"Hepatology"},{"issue":"2","key":"3765_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/practneurol-2019-002321","volume":"20","author":"V Li","year":"2020","unstructured":"Li V, et al. A practical approach to assessing and managing sexual dysfunction in multiple sclerosis. Pract Neurol. 2020;20(2):122\u201331.","journal-title":"Pract Neurol"},{"issue":"1","key":"3765_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.20471\/acc.2018.57.01.06","volume":"57","author":"A Starc","year":"2018","unstructured":"Starc A, et al. Female sexual function and dysfunction: a cross-national prevalence study in Slovenia. Acta Clin Croatica. 2018;57(1):52.","journal-title":"Acta Clin Croatica"},{"issue":"1","key":"3765_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12905-022-02134-w","volume":"23","author":"N Salari","year":"2023","unstructured":"Salari N, et al. The risk of sexual dysfunction associated with alcohol consumption in women: a systematic review and meta-analysis. BMC Womens Health. 2023;23(1):1\u20137.","journal-title":"BMC Womens Health"},{"issue":"1","key":"3765_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12883-022-02884-y","volume":"22","author":"M Gaviria- Carrillo","year":"2022","unstructured":"Gaviria- Carrillo M, Bueno-Florez SJ, Ortiz-Salas PA. Assessment of sexual dysfunction in patients with multiple sclerosis: a perspective from neurologist. BMC Neurol. 2022;22(1):372.","journal-title":"BMC Neurol"},{"key":"3765_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-020-01560-x","volume":"10","author":"M Dastoorpoor","year":"2021","unstructured":"Dastoorpoor M, et al. Prevalence of sexual dysfunction in men with multiple sclerosis: a systematic review and meta-analysis. Syst Reviews. 2021;10:1\u20139.","journal-title":"Syst Reviews"},{"issue":"4","key":"3765_CR12","first-page":"408","volume":"14","author":"A Azimi","year":"2019","unstructured":"Azimi A, et al. Prevalence of sexual dysfunction in women with multiple sclerosis: a systematic review and meta-analysis. Maedica. 2019;14(4):408.","journal-title":"Maedica"},{"issue":"7","key":"3765_CR13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/j.1743-6109.2012.02746.x","volume":"9","author":"JJ Keller","year":"2012","unstructured":"Keller JJ, Liang Y-C, Lin H-C. Association between multiple sclerosis and erectile dysfunction: a nationwide case-control study. J Sex Med. 2012;9(7):1753\u20139.","journal-title":"J Sex Med"},{"issue":"13\u201314","key":"3765_CR14","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1111\/jocn.14378","volume":"27","author":"I Egerod","year":"2018","unstructured":"Egerod I, Wulff K, Petersen MC. Experiences and informational needs on sexual health in people with epilepsy or multiple sclerosis: a focus group investigation. J Clin Nurs. 2018;27(13\u201314):2868\u201376.","journal-title":"J Clin Nurs"},{"issue":"5","key":"3765_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.msard.2014.06.005","volume":"3","author":"E Fox","year":"2014","unstructured":"Fox E, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, evaluate patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Scler Relat Disorders. 2014;3(5):607\u201319.","journal-title":"Multiple Scler Relat Disorders"},{"issue":"1","key":"3765_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-014-0220-1","volume":"14","author":"J Calkwood","year":"2014","unstructured":"Calkwood J, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient-and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurol. 2014;14(1):1\u201311.","journal-title":"BMC Neurol"},{"doi-asserted-by":"crossref","unstructured":"Wu J, et al. Perceived cognitive impairment is associated with sexual dysfunction in people with multiple sclerosis: a 2.5-year follow-up study of a large international cohort. Multiple Sclerosis and Related Disorders; 2020. p. 45.","key":"3765_CR17","DOI":"10.1016\/j.msard.2020.102410"},{"issue":"5","key":"3765_CR18","first-page":"601","volume":"13","author":"Khadijeh","year":"2014","unstructured":"Khadijeh, Mohammadi, et al. Validation of the Persian version of multiple sclerosis intimacy and sexuality Questionnaire-19 (MSISQ-19). Payesh (Health Monitor) J. 2014;13(5):601\u20137.","journal-title":"Payesh (Health Monitor) J"},{"issue":"2","key":"3765_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/19317611.2016.1259705","volume":"29","author":"SD Y\u0131lmaz","year":"2017","unstructured":"Y\u0131lmaz SD, et al. Sexual life of women with multiple sclerosis: a qualitative study. Int J Sex Health. 2017;29(2):147\u201354.","journal-title":"Int J Sex Health"},{"issue":"2","key":"3765_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2012.10.005","volume":"2","author":"B Orasanu","year":"2013","unstructured":"Orasanu B, et al. Sexual dysfunction in patients with multiple sclerosis. Multiple Scler Relat Disorders. 2013;2(2):117\u201323.","journal-title":"Multiple Scler Relat Disorders"},{"issue":"1","key":"3765_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2012.08.019","volume":"324","author":"DB \u00c7elik","year":"2013","unstructured":"\u00c7elik DB, et al. Sexual dysfunction \u0131n multiple sclerosis: gender differences. J Neurol Sci. 2013;324(1):17\u201320.","journal-title":"J Neurol Sci"},{"issue":"6","key":"3765_CR22","doi-asserted-by":"publisher","first-page":"e00699","DOI":"10.1002\/brb3.699","volume":"7","author":"P Bartnik","year":"2017","unstructured":"Bartnik P, et al. Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis. Brain Behav. 2017;7(6):e00699.","journal-title":"Brain Behav"},{"issue":"2","key":"3765_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/jsm.12397","volume":"11","author":"H Gumus","year":"2014","unstructured":"Gumus H, Akpinar Z, Yilmaz H. Effects of multiple sclerosis on female sexuality: a controlled study. J Sex Med. 2014;11(2):481\u20136.","journal-title":"J Sex Med"},{"issue":"12","key":"3765_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/1352458512438239","volume":"18","author":"DM Balak","year":"2012","unstructured":"Balak DM, et al. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Multiple Scler J. 2012;18(12):1705\u201317.","journal-title":"Multiple Scler J"},{"key":"3765_CR25","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1007\/s00415-020-09771-x","volume":"267","author":"F Patti","year":"2020","unstructured":"Patti F, et al. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. J Neurol. 2020;267:1812\u201323.","journal-title":"J Neurol"},{"issue":"2","key":"3765_CR26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.46.2.552","volume":"46","author":"LK Neilley","year":"1996","unstructured":"Neilley LK, et al. Side effect profile of interferon beta-lb in MS: results of an open label trial. Neurology. 1996;46(2):552\u20133.","journal-title":"Neurology"},{"issue":"3","key":"3765_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eurpsy.2005.09.013","volume":"21","author":"J-L Goeb","year":"2006","unstructured":"Goeb J-L, et al. Psychiatric side effects of interferon-\u03b2 in multiple sclerosis. Eur Psychiatry. 2006;21(3):186\u201393.","journal-title":"Eur Psychiatry"},{"issue":"5","key":"3765_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/135245859600200502","volume":"2","author":"D Mohr","year":"1996","unstructured":"Mohr D, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: relationship to adherence to treatment. Multiple Scler J. 1996;2(5):222\u20136.","journal-title":"Multiple Scler J"},{"issue":"4","key":"3765_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.18502\/ijrm.v20i4.10897","volume":"20","author":"B Afshar","year":"2022","unstructured":"Afshar B, et al. The most effective sexual function and dysfunction interventions in individuals with multiple sclerosis: a systematic review and meta-analysis. Int J Reproductive Biomed. 2022;20(4):241.","journal-title":"Int J Reproductive Biomed"},{"doi-asserted-by":"crossref","unstructured":"Abolfazli R et al. Quality of life assessment in patients with multiple sclerosis receiving interferon beta-1a: a comparative longitudinal study of Avonex and its biosimilar CinnoVex International Scholarly Research Notices, 2012. 2012.","key":"3765_CR30","DOI":"10.5402\/2012\/786526"},{"key":"3765_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fneur.2015.00097","volume":"6","author":"A Kunkel","year":"2015","unstructured":"Kunkel A, et al. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing\u2013remitting multiple sclerosis. Front Neurol. 2015;6:97.","journal-title":"Front Neurol"},{"issue":"7","key":"3765_CR32","first-page":"A762","volume":"18","author":"R Iyer","year":"2015","unstructured":"Iyer R, et al. Relapsing remitting multiple sclerosis patients initiated on oral Dmf Report A Better Quality of Life Compared to patients on platform therapies as measured by Eq-5d. Value Health. 2015;18(7):A762.","journal-title":"Value Health"},{"doi-asserted-by":"crossref","unstructured":"Ozel O et al. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives. Patient Relat Outcome Measures, 2019: p. 373\u201384.","key":"3765_CR33","DOI":"10.2147\/PROM.S168095"},{"issue":"4","key":"3765_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/13524585211031128","volume":"28","author":"E Longinetti","year":"2022","unstructured":"Longinetti E, et al. Risk of depression in multiple sclerosis across disease-modifying therapies. Multiple Scler J. 2022;28(4):632\u201341.","journal-title":"Multiple Scler J"},{"issue":"1","key":"3765_CR35","doi-asserted-by":"crossref","first-page":"205521732211442","DOI":"10.1177\/20552173221144229","volume":"9","author":"G Comi","year":"2023","unstructured":"Comi G, et al. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: a multicentre Italian wearable tracker study. Multiple Scler Journal\u2013Experimental Translational Clin. 2023;9(1):20552173221144229.","journal-title":"Multiple Scler Journal\u2013Experimental Translational Clin"},{"doi-asserted-by":"crossref","unstructured":"V\u00e1zquez SM et al. Association between sexual function in women and sleep quality. Front Med, 2023. 10.","key":"3765_CR36","DOI":"10.3389\/fmed.2023.1196540"},{"issue":"6","key":"3765_CR37","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3390\/jcm10061234","volume":"10","author":"A Carotenuto","year":"2021","unstructured":"Carotenuto A, et al. Physical exercise moderates the effects of disability on depression in people with multiple sclerosis during the COVID-19 outbreak. J Clin Med. 2021;10(6):1234.","journal-title":"J Clin Med"},{"issue":"6","key":"3765_CR38","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3390\/jcm12062215","volume":"12","author":"C Scandurra","year":"2023","unstructured":"Scandurra C, et al. Sexual dysfunction in people with multiple sclerosis: the role of Disease Severity, Illness Perception, and Depression. J Clin Med. 2023;12(6):2215.","journal-title":"J Clin Med"},{"issue":"null","key":"3765_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2147\/NDT.S45144","volume":"9","author":"A Lugaresi","year":"2013","unstructured":"Lugaresi A, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9(null):893\u2013914.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"3765_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/acn3.700","volume":"6","author":"BL Vollmer","year":"2019","unstructured":"Vollmer BL, et al. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019;6(2):252\u201362.","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"3765_CR41","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/acn3.51111","volume":"7","author":"BL Vollmer","year":"2020","unstructured":"Vollmer BL, et al. Rituximab versus Natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020;7(9):1466\u201376.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"3765_CR42","doi-asserted-by":"crossref","first-page":"205521731878198","DOI":"10.1177\/2055217318781989","volume":"4","author":"D Robertson","year":"2018","unstructured":"Robertson D, et al. Patient perceived changes in sexual dysfunction after initiation of natalizumab for multiple sclerosis. Multiple Scler journal\u2013experimental Translational Clin. 2018;4(2):2055217318781989.","journal-title":"Multiple Scler journal\u2013experimental Translational Clin"},{"doi-asserted-by":"crossref","unstructured":"Achtnichts L et al. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS). BMJ Neurol open, 2023. 5(1).","key":"3765_CR43","DOI":"10.1136\/bmjno-2022-000304"},{"doi-asserted-by":"crossref","unstructured":"Foley JF et al. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence, 2017: p. 1035\u201348.","key":"3765_CR44","DOI":"10.2147\/PPA.S134865"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03765-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T18:30:35Z","timestamp":1732473035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03765-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03765-2","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants. This study is approved by the Tehran University of Medical Sciences Ethical Committee with the ethical code; IR.TUMS.SINAHOSPITAL.REC.1401.125.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}